» Articles » PMID: 36902237

IGFBP-6 Network in Chronic Inflammatory Airway Diseases and Lung Tumor Progression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Mar 11
PMID 36902237
Authors
Affiliations
Soon will be listed here.
Abstract

The lung is an accomplished organ for gas exchanges and directly faces the external environment, consequently exposing its large epithelial surface. It is also the putative determinant organ for inducing potent immune responses, holding both innate and adaptive immune cells. The maintenance of lung homeostasis requires a crucial balance between inflammation and anti-inflammation factors, and perturbations of this stability are frequently associated with progressive and fatal respiratory diseases. Several data demonstrate the involvement of the insulin-like growth factor (IGF) system and their binding proteins (IGFBPs) in pulmonary growth, as they are specifically expressed in different lung compartments. As we will discuss extensively in the text, IGFs and IGFBPs are implicated in normal pulmonary development but also in the pathogenesis of various airway diseases and lung tumors. Among the known IGFBPs, IGFBP-6 shows an emerging role as a mediator of airway inflammation and tumor-suppressing activity in different lung tumors. In this review, we assess the current state of IGFBP-6's multiple roles in respiratory diseases, focusing on its function in the inflammation and fibrosis in respiratory tissues, together with its role in controlling different types of lung cancer.

Citing Articles

[Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance 
and Lung Cancer].

Chen X, Chen P Zhongguo Fei Ai Za Zhi. 2024; 27(10):755-762.

PMID: 39631832 PMC: 11629090. DOI: 10.3779/j.issn.1009-3419.2024.106.27.


Tibial cortex transverse transport surgery improves wound healing in patients with severe type 2 DFUs by activating a systemic immune response: a cross-sectional study.

Yu L, Zhang D, Yin Y, Li X, Bai C, Zhou Q Int J Surg. 2024; 111(1):257-272.

PMID: 38954658 PMC: 11745691. DOI: 10.1097/JS9.0000000000001897.


Key processes in tumor metastasis and therapeutic strategies with nanocarriers: a review.

Li H, Huang H, Tan H, Jia Q, Song W, Zhang Q Mol Biol Rep. 2024; 51(1):197.

PMID: 38270746 DOI: 10.1007/s11033-023-08910-7.

References
1.
Macaulay V . Insulin-like growth factors and cancer. Br J Cancer. 1992; 65(3):311-20. PMC: 1977607. DOI: 10.1038/bjc.1992.65. View

2.
Wu H, Suzuki T, Carey B, Trapnell B, McCormack F . Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages. J Biol Chem. 2011; 286(17):14932-40. PMC: 3083236. DOI: 10.1074/jbc.M110.182170. View

3.
Tang D, Yao R, Zhao D, Zhou L, Wu Y, Yang Y . Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy. Sci Rep. 2018; 8(1):3917. PMC: 5834489. DOI: 10.1038/s41598-018-22257-1. View

4.
Benbassat C, Lazarus D, Cichy S, Evans T, Moldawer L, Lowry S . Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro. Horm Metab Res. 1999; 31(2-3):209-15. DOI: 10.1055/s-2007-978721. View

5.
Alfaro-Arnedo E, Lopez I, Pineiro-Hermida S, Canalejo M, Gotera C, Sola J . IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. Oncogene. 2022; 41(28):3625-3639. PMC: 9184253. DOI: 10.1038/s41388-022-02376-w. View